

**PERSONAL INFORMATION****Maria Concepcion Prieto Yerro****WORK EXPERIENCE**

---

- 2005- Present **Technical adviser for the Department of Drugs for Human Use**  
Spanish Agency for Drugs and Medical Devices (Spain)  
Head of the Centralised Procedure Unit (coordinating all activities related to the centralised procedure applications)  
CHMP member from Spain
- 2001- 2005 **Head of Service of Clinical Assessment and Pharmacology**  
Spanish Agency for Drugs and Medical Devices (Spain)  
Clinical assessor (Cardiovascular, SNC, ophtalmology, lung diseases, urology)
- 1994- 1996 **Coordinator of the Program of Rational of Drugs in Primary Care**  
National Health Service - Primary Care - Sector 4 Madrid (Spain)  
Drug information activities
- 1992- 1994 **Assessor of the Department of Health Promotion**  
National School of Health (Spain)  
Health education, health promotion, use of drugs
- 1990- 1992 **Assessor of the Division of Pharmaceutical Provision**  
Ministry of Health - Madrid (Spain)  
Development and implementation of the Program of Rational Use of Drugs in Primary Care
- 1985- 1990 **General practitioner - Primary care**  
National Health Service (Spain)  
Clinical practice in primary care

**EDUCATION AND TRAINING**

---

- 1977- 1984 **Degree in Medicine and Surgery (MD), 1984**  
School of Medicine. Universidad Complutense de Madrid (Spain)  
Medicine and Surgery
- 1994- **PhD (Doctorate), 1994**  
Universidad Autónoma de Madrid - Spain (Spain)  
Rational Use of Drugs in Primary Care
- 1996- 2000 **Specialist in Clinical Pharmacology**  
Hospital Universitario Clínico de San Carlos- Madrid (Spain)  
Two years of rotations in internal medicine, haematology, nephrology and neurology units. Four years as duty doctor in emergency department. Four-year training in matters related to clinical pharmacology issues (drug utilisation studies, drug monitoring...)

**ADDITIONAL INFORMATION**

---

Expertise Ophtalmology

Publications

- 1.- Prieto Yerro C, López Corbalán JC. Utilización de antihipertensivos en Baleares y su análisis comparativo en el periodo 1981-86. *Inf Ter Segur Soc* 1988; 12:97-9
- 2.- Garcia Iñesta A, Prieto Yerro C. Utilización de antiinfecciosos en España en el periodo 1981-1987. *Inf Ter Segur Soc* 1988;12:181-92
- 3.- Iñesta A, Prieto Yerro C. Utilización de cloranfenicol en el periodo 1982-1987. *Inf Ter Segur Soc* 1989;13:148-59
- 4.- Prieto I, Prieto C, Sacristán A. Utilización de analgésicos narcóticos en el tratamiento del dolor. *Inf Ter Sist Nac Salud* 1991;15:180-6
- 5.- Cortés E, Cuesta T, Ferré P, Rodríguez A, Prieto C. Nuevos principios activos comercializados en España en 1991. *Inf Ter Sist Nac Salud* 1992;16(4):79-95
- 6.- Sacristán Rodea A, Terol García E, Prieto Yerro C. Estudio de un programa de cuidados paliativos a domicilio. Atención Primaria. Area 4 del INSALUD. Madrid. 1996
- 7.- Palanca Sánchez I, Prieto Yerro C, Sacristán Rodea A. Prestación y políticas farmacéuticas. La salud y los servicios sanitarios en la Comunidad de Madrid. *AMA* 1996:327-333
- 8.- García Arenillas M, Prieto Yerro C, Portolés Pérez A. Utilización de medicamentos en el embarazo, lactancia, niños y ancianos. *Medicine* 1999;130:6158-66
- 9.- Moreno González A, Vargas Castrillón E, Gassent Balaguer C, Laredo Velasco L, Prieto Yerro C. Guía farmacológica en podología. Federación Española de Podólogos. Madrid, 1999
- 10.- Prieto Yerro C, Vargas Castrillón E. Uso de AINE en pacientes con patología crónica asociada. *Inf Ter Sist Nac Salud* 2000;24(4):85-91
- 11.- Prieto Yerro C, Pérez López C, Rodríguez Bernardino A, Martínez Martínez R, del Potro Gómez E, Alvarez Carmona A. Relapsing pancytopenia following exposure and re-exposure to cyanamide. *Eur J Haematology* 2000;65:1-2
- 12.- Prieto Yerro C, Vargas Castrillón E, Laredo Velasco L, Pérez-Cecilia E, Ambit Avila I, Picazo de la Garza JJ. Utilización de Anfotericina B no convencional en el hospital Clínico de San Carlos. *Rev Esp Salud Pública* 2000;74:345-53
- 13.- Prieto Yerro C, Rodríguez Bernardino A, Vargas Castrillón E. Utilización de propacetamol en el Hospital Clínico de San Carlos. *Atención Farmacéutica* 2000; 2(6): 534-8
- 14.- Prieto Yerro C, Vargas Castrillón E, Laredo Velasco L, Pérez-Cecilia E, Ambit Avila I, Picazo de la Garza JJ. Modificación en el patrón de uso de anfotericina B no convencional tras una intervención formativa en el hospital Clínico de San Carlos. *Rev Esp Salud Pública* 2001;75(2):353-60
- 15.- Moreno González, A; Prieto Yerro, C; Vargas Castrillón, E, Laredo Velasco, L, Asenjo Correa, S. Profilaxis del tromboembolismo venoso en paciente no quirúrgicos. *Medifam* 2002; 12 (6): 369-378
- 16.- M Berntgen, H. Enzmann; E. Schabel, C. Prieto Yerro, A. Gómez-Outes, T. Samonson, J. Musaus. Linaclotide for treatment of irritable bowel syndrome-The view of the European regulators. *Dig Liver Dis.* 2013 Sep;45(9):724-6.
- 17.- Cortes-Blanco A, Prieto Yerro C, et al. Florbetapir (18F) for brain amyloid positron emission tomography: Highlights on the European marketing approval. *Alzheimer's and Dementia* 2014;10 (5): S395S399.
- 18.- Haas M, Prieto Yerro C et al. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchene muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. *Neuromuscular disorder* 2015; 25 (1): 513
- 19.- de Wit M, Cooper C, Tugwell P, Bere N6, Kirwan J, Conaghan PG, Roberts C, Aujoulat I, Al-Daghri N, Araujo de Carvalho I, Barker M, Bedlington N, Brandi ML, Bruyère O, Burllet N, Halbout P, Hilgsmann M, Jiwa F, Kanis JA, Laslop A, Lawrence W2, Pinto D, Prieto Yerro C, Rabenda V, Rizzoli R, Scholte-Voshaar M, Vlaskovska M, Reginster JY. Practical guidance for engaging patients

in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). *Aging Clinical and Experimental Research* 2019; 31(7), 905-915

20.- JeanYves Reginster et al. Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. *Aging Clinical and Experimental Research* 2020, Jul 31. <https://doi.org/10.1007/s40520-020-01663-4>

#### Projects

**Memberships** From 2005-2010 alternate at the CHMP from Spain.  
From 2003-2006 member of the Ethics Committee of University Hospital of Mostoles (Madrid, Spain).  
From 2013 member of the Patients' and Consumers' Working Party.  
From 2016 member of the Respiratory Drafting Group.  
Member of the Spanish National Board on Human Medicines.  
Peer Reviewer for the *Revista Española de Salud Pública*.

**Other Relevant Information** Master's degree in Methodology of the Investigation (400 h)